Welcome to our dedicated page for Pds Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on Pds Biotechnology Corporation stock.
PDS Biotechnology Corporation (Nasdaq: PDSB) is a late-stage immunotherapy company developing investigational cancer therapies based on its Versamune® platform and IL-12 immunocytokine technology. News about PDS Biotech centers on the clinical and regulatory progress of its lead HPV16-targeted immunotherapy PDS0101 and its tumor-targeting IL-12 fused antibody drug conjugate PDS01ADC.
On this page, readers can follow company announcements on pivotal and mid-stage trials, including the VERSATILE-002 Phase 2 study and the VERSATILE-003 Phase 3 trial in HPV16-positive recurrent and/or metastatic head and neck squamous cell cancers. Updates often cover final survival and progression-free survival data, sub-analyses in specific patient subgroups such as low PD-L1 (CPS 1–19) cohorts, and efforts to align with the U.S. Food and Drug Administration on potential accelerated approval pathways.
PDS Biotech news also highlights translational research presented at scientific meetings like the Society for Immunotherapy of Cancer, where investigators have reported immune biomarker signatures, natural killer cell reprogramming, and expansion of stem-like memory T cells associated with PDS0101 and PDS01ADC. Additional coverage includes National Cancer Institute-led Phase 2 trials in metastatic colorectal and other advanced solid tumors, intellectual property developments such as new composition of matter patents for PDS0101, and capital markets events including registered direct offerings disclosed in Form 8-K filings.
Investors and observers who want to track PDSB can use this news feed to monitor clinical milestones, regulatory interactions, scientific data presentations, and financing activities that may influence the company’s development programs and overall outlook.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. The company will update on three ongoing PDS0101 Phase 2 clinical trials and progress on PDS0102 and PDS0103 into human clinical trials. CEO Dr. Frank Bedu-Addo will also join an oncology panel discussion. The company’s innovative Versamune® technology aims to enhance T-cell responses against various cancers. Investors can register online for the event and access a webcast replay post-conference.
PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30, 2021. The presentation on September 28 at 4:40 PM EDT will cover updates on three ongoing Phase 2 clinical trials for PDS0101, along with advancements for investigational products PDS0102 and PDS0103. Following the conference, a replay will be available on the company's website. PDS Biotech focuses on cancer therapies utilizing its Versamune® T-cell activating technology.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced that its VERSATILE-002 Phase 2 study for treating advanced HPV16-associated head and neck cancer reached a preliminary safety benchmark. No dose-limiting toxicities were observed in the initial 12 patients. The trial will continue enrollment for efficacy evaluation among 17 checkpoint inhibitor (CPI) naïve patients and 21 CPI refractory patients. The study aims to advance based on tumor response criteria. PDS0101, in combination with KEYTRUDA, targets an unmet medical need in advanced cancer treatment.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced an equity award to Gregory Reid, its new VP of Program Development, as an inducement for joining the company. This award includes 63,800 shares with an exercise price of $14.99, vesting over four years. Reid brings over 30 years of pharmaceutical industry experience, particularly in oncology product development. His expertise aims to advance PDS Biotech's innovative cancer immunotherapy pipeline, leveraging its proprietary Versamune® technology, which targets various cancers effectively.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 21-23, 2021. The management will present updates on three ongoing Phase 2 clinical trials for PDS0101 and developments of PDS0102 and PDS0103 in human clinical trials. The presentation is scheduled for September 21, 2021, at 3:45 PM EDT. A webcast will follow on the company's investor website. PDSB focuses on innovative cancer therapies utilizing its proprietary Versamune® T-cell activating technology.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced the completion of enrollment in the lead-in safety cohort for its VERSATILE-002 Phase 2 study. This trial evaluates the efficacy and safety of the combination of PDS0101 and KEYTRUDA® for treating HPV16-associated head and neck cancer. The study includes approximately 100 patients across 25 centers in the U.S. Preliminary data shows promising responses, with 83% of CPI naïve patients showing tumor reduction. The company aims to address the significant unmet medical needs in advanced HPV-related cancers.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the HC Wainwright 23rd Annual Global Investment Conference, set for September 13-15, 2021. The management will present updates on three ongoing Phase 2 clinical trials for PDS0101, along with progress on PDS0102 and PDS0103, which are entering human clinical trials. The presentation will be available on demand starting September 13 at 7:00 am EDT on the company’s website. PDS Biotech specializes in immunotherapy based on its Versamune® technology, targeting various cancers including breast and lung cancer.
PDS Biotechnology Corporation (Nasdaq: PDSB) reported a net loss of $0.6 million, or ($0.03) per share, for Q2 2021, a reduction from $2.9 million in Q2 2020, primarily due to $4.5 million from NJ tax benefit sales. Significant clinical results were highlighted, showing tumor reduction in 83% of HPV16-positive patients not previously treated with checkpoint inhibitors and 58% in those who had. The company completed a $52 million public offering to advance its pipeline and appointed new experts to its Scientific Advisory Board.
PDS Biotechnology Corporation (Nasdaq: PDSB) announced presentations at various investor conferences in Q3 2021, highlighting interim data on its lead asset, PDS0101. At the ASCO 2021 Meeting, results showed tumor reduction in 83% of advanced cancer patients who failed prior treatments, and 58% in those who also failed checkpoint inhibitors. PDS0101 targets HPV16-positive cancers and is involved in ongoing Phase 2 studies. Upcoming conferences include BTIG on August 10, HC Wainwright on September 14, and Cantor on September 27.
PDS Biotechnology Corporation (Nasdaq: PDSB) will release its Q2 2021 financial results on August 12, 2021, before the market opens. Following the release, a conference call will be held at 8:00 am ET to review the results and provide a business update. PDS Biotech is focused on developing novel cancer therapies using its proprietary Versamune T-cell activating technology, with its lead product PDS0101 currently in three Phase 2 clinical studies targeting HPV-associated cancers. Interim results have shown strong efficacy in advanced, treatment-resistant cancers.